Successful ADCs must achieve potent on-target cytotoxicity while minimizing off-target effects on healthy cells. Off-target toxicities to normal hematopoietic cells are the most frequently reported adverse events associated with ADCs. These off-target effects can be caused when normal cells express the ADC target. However, the unforeseen and unexpected off-target toxicities to the hematopoietic compartment, with targets not expressed on hematopoietic cells, suggest that linker stability and the highly potent payloads may play the most significant role in off-target toxicity. The featured speakers will also discuss in vitro assays to quickly evaluate these components and demonstrate how linker stability and payload selection contribute to these adverse outcomes.
Register for this webinar to gain practical strategies for advancing ADC development with confidence, whether you’re new to ADCs or optimizing your next therapeutic candidate.
Speakers
Dr. Emer Clarke, VP Cell Biology, Discovery Life Sciences
Dr. Emer Clarke has over 25 years of experience in stem cell biology, spanning both clinical and industrial settings. She plays a pivotal role in driving innovations and managing Discovery’s scientific operations, including research and development and client services. Dr. Clarke is also actively involved in client affairs, offering one-on-one consultations, study design and data analysis.
Message Presenter
Dr. Shawn Fahl, VP Lab Operations, Cell Services & R&D, Biospecimens, Discovery Life Sciences
Dr. Shawn Fahl earned his PhD in Microbiology from the University of Virginia and completed a postdoctoral fellowship at Fox Chase Cancer Center. With expertise in transcriptional regulation of lymphocyte development, Dr. Fahl joined Discovery in 2017 to pioneer analytical pipelines for single-cell evaluation of primary human biospecimens.
Message PresenterWho Should Attend?
This webinar will appeal to:
- ADC developers and scientists
- Oncology drug developers and researchers
- Preclinical and translational scientists focused on in vitro assay development
- Biopharma professionals involved in ADC candidate selection and optimization
What You Will Learn
Attendees will:
- Understand why ADC programs benefit from a “fail faster” approach to reduce late-stage attrition and accelerate development
- Learn how early in vitro testing helps identify both on-target efficacy and off-target toxicity risks
- See how tumoroid models offer more physiologically relevant insights into ADC activity across diverse tumor types
- Explore how hematopoietic assays can predict off-target effects like myelosuppression and neutropenia
Xtalks Partner
Discovery Life Sciences
Discovery Life Sciences is a global leader in biospecimens and specialty lab services, enabling the discovery and development of groundbreaking therapeutics and diagnostics. With a robust portfolio of human biospecimens and cellular starting material, preclinical ADME-tox solutions, and cutting-edge specialty lab services, we provide our partners with the tools, data and expertise they need to succeed. From genomics and proteomics to cell biology and molecular pathology, our comprehensive service offerings support every phase of the scientific journey, from research through clinical trials. For more information, visit www.dls.com.
Related Webinars
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account